Napredna pretraga

Pregled bibliografske jedinice broj: 87557

Bisphosphonate therapy for osteogenesis imperfecta


Huzjak, Nevenka; Barišić, Ingeborg; Rešić, Arnes; Kušec, Vesna; Antičević, Darko; Dodig, Damir; Primorac, Dragan
Bisphosphonate therapy for osteogenesis imperfecta // European Human Genetics Conference 2002 in conjunction with European Meeting on Psychosocial Aspects of Genetics (EMPAG 2002) : Abstracts ; u: European Journal of Human Genetics 10 (2002) (S1)
Strasbourg, Francuska, 2002. str. 301-301 (predavanje, nije recenziran, sažetak, znanstveni)


Naslov
Bisphosphonate therapy for osteogenesis imperfecta

Autori
Huzjak, Nevenka ; Barišić, Ingeborg ; Rešić, Arnes ; Kušec, Vesna ; Antičević, Darko ; Dodig, Damir ; Primorac, Dragan

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
European Human Genetics Conference 2002 in conjunction with European Meeting on Psychosocial Aspects of Genetics (EMPAG 2002) : Abstracts ; u: European Journal of Human Genetics 10 (2002) (S1) / - , 2002, 301-301

Skup
European Human Genetics Conference 2002 ; European Meeting on Psychosocial Aspects of Genetics 2002

Mjesto i datum
Strasbourg, Francuska, 25.-28.05.2002

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Nije recenziran

Ključne riječi
Osteogenesis imperfecta ; bisphosphonates

Sažetak
Severe osteogenesis imperfecta (OI) is a hereditary disorder characterised by increased bone fragility and progressive bone deformity. So far, no effective medical treatment is avaliable. As secondary osteoporosis is an important feature of OI, antiresorptive activity of the aminobisphosphonates may improve clinical outcome in children. Aimwas to asses the clinical impact of the administration of bisphosponates in Croatian OI patients. We report results of 1-3 years treatment with intravenous pamidronate (APD) in seven children (four girls) of age 3 months - 11 years at entry, with severe OI. Pamidronate was administered in cycles as monthly infusions at a daily dose of 1-1.5 mg/kg during 6 months following pause for three months, or the same dose for three days every four months. Following tratmend DEXA measurements showed a gradual increase in bone density in all patients. Number of confirmed fractures decreased in all. The reduction in pain and improvement in well-being and ability were impressive in two boys who had been confined to a wheelchair and now they walk using crutches. Acute phase reactions were noted during first infusion cycle in two children and asymptomatic hypocalcaemia in three children. Three children gained excessive weight. Although bisphosponates do not correct basic abnormalities in OI, they significantly alter the natural course of the disease and improve patients quality of life. For the time being they seem not only effective but also devoid of any adverse effects on bone growth and remodelling.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita



POVEZANOST RADA


Projekt / tema
072777
141009

Ustanove
Klinika za dječje bolesti Medicinskog fakulteta,
KBC Split

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE